H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on IO Biotech (IOBT – Research Report) today and set a price target of $8.00. The company’s shares closed yesterday at $1.45.
According to TipRanks, Bodnar is an analyst with an average return of -10.2% and a 30.95% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as IO Biotech, Agenus, and NovoCure.
IO Biotech has an analyst consensus of Strong Buy, with a price target consensus of $8.00.
See Insiders’ Hot Stocks on TipRanks >>
IOBT market cap is currently $95.53M and has a P/E ratio of -0.56.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IOBT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Read More on IOBT:
- IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
- IO Biotech Announces Participation in Upcoming Investor Conferences
- IO Biotech files to sell 74.13M shares of common stock for holders
- IO Biotech reports Q2 EPS (74c), consensus (64c)
- IO Biotech Announces 2023 Second Quarter Results
